Methylethyltryptamine

MET was briefly mentioned in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) and other publications, where he has stated it to be orally active as a psychedelic at doses of 80 to 100mg. Its duration, onset, and peak were not provided. Very little information is available on the effects of MET. However, its effects have been reported to include hallucinations, euphoria, tactile enhancement, cognitive effects, pupil dilation, muscle cramps, teeth grinding, and increased heart rate and blood pressure. ==Interactions==

Pharmacodynamics MET is a serotonin 5-HT2A and 5-HT2C receptor partial agonist. It shows very weak activity as an agonist of the serotonin 5-HT1A and 5-HT2B receptors. In addition to acting at the serotonin 5-HT2 receptors, MET is a serotonin releasing agent with lower potency. It produces the head-twitch response, a behavioral proxy of psychedelic effects, in animals. ==Chemistry==

MET, also known as N-methyl-N-ethyltryptamine, is a substituted tryptamine derivative. It is closely related to N,N-dimethyltryptamine (DMT) and to other N,N-dialkylated tryptamines. Analogues Analogues of MET besides DMT include DET, DPT, DiPT, DBT, MiPT, MBT, EPT, EiPT, and PiPT, among others. Derivatives of MET include 4-HO-MET, 5-HO-MET, 5-MeO-MET, bretisilocin (5-fluoro-MET; GM-2505), and 7-F-5-MeO-MET, among others. ==History==

MET appears to have first been described in the literature by 1981. It was specifically mentioned in Michael Valentine Smith's Psychedelic Chemistry. Subsequently, MET was briefly described in Alexander Shulgin's TiHKAL (Tryptamines I Have Known and Loved) in 1997. MET was encountered as a novel designer drug in Europe in 2014. ==Society and culture==

Legal status Canada MET is not a controlled substance in Canada as of 2025. United States MET is not an explicitly controlled substance in the United States. However, it could be considered a controlled substance under the Federal Analogue Act if intended for human consumption. ==See also==